Speaking over the companys earnings call, Srinivas Sadu, Executive Chairman Gland Pharma, said, Our GLP-1 strategy gained momentum last quarter and and this quarter th drug was launched in UK and Australia. We are aggressively increasing our GLP-1/Pen/cartridge capacity from 40 million to 140 million units, and the battery acceptance test (BAT) scheduled to be completed by September 2025, the executive chairman added
Introduction of Generics and Oral Formulations: Market accessibility has improved through the approval of the first generic liraglutide (Victoza) earlier this year and generic exenatide last month
doi:10.1371/JOURNAL.PONE.0271267 19
In a recently published landmark phase III study in patients with overweight or obesity (STEP 1), greater reductions in body weight were observed after 68 weeks of treatment with once-weekly semaglutide 2.4 mg vs
Effects of GLP-1 receptor agonists on gastric emptying: evidence of tachyphylaxis with long-term use
Insert the needle in the center of the v-shape to administer the B12 injection